Burrows Scott L 4
4 · Spyre Therapeutics, Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Spyre Therapeutics (SYRE) CFO Scott Burrows Exercises Options, Sells Shares
What Happened
- Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics (SYRE), exercised 7,500 option shares at $14.50 per share (total cost $108,750) and immediately sold those 7,500 shares in two open-market blocks on July 1, 2026 for aggregate proceeds of $658,039. The sales were reported as 5,775 shares at a weighted average $87.55 (≈ $505,601) and 1,725 shares at a weighted average $88.37 (≈ $152,438). The filing also shows a derivative conversion line (7,500 shares at $0.00) reflecting the exercise/conversion.
Key Details
- Transaction date: July 1, 2026; Form filed July 2, 2026 (timely).
- Option exercise: 7,500 shares exercised at $14.50 (cost $108,750).
- Sales: 5,775 shares at weighted avg $87.55 (range $87.13–$88.05); 1,725 shares at weighted avg $88.37 (range $88.17–$89.01). Total proceeds ≈ $658,039.
- Shares owned after transaction: Not specified in the filing.
- Footnotes: Sales executed pursuant to a Rule 10b5-1 trading plan adopted Nov 10, 2025 (F1). Price rows are weighted averages; the filer will provide per-price breakdowns on request (F2, F3). Filing also discloses existing RSUs (67,476) and option grant details/vesting (F4, F5).
- Filing timeliness: No late filing indicated.
Context
- This was an exercise followed by immediate sale of the resulting shares (effectively a cashless exercise / sale of all exercised shares). The presence of a 10b5-1 plan indicates the sales were pre-arranged. The filing includes background on outstanding options and RSUs (vesting schedules) but does not state Burrows’ post-transaction holdings; contact the company or review the full Form 4 for complete ownership details.
Insider Transaction Report
Form 4
Burrows Scott L
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-07-01$14.50/sh+7,500$108,750→ 105,494 total - Sale
Common Stock
[F1][F2]2026-07-01$87.55/sh−5,775$505,601→ 99,719 total - Sale
Common Stock
[F1][F3][F4]2026-07-01$88.37/sh−1,725$152,438→ 97,994 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-07-01−7,500→ 352,357 totalExercise: $14.50Exp: 2033-09-01→ Common Stock (7,500 underlying)
Footnotes (5)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.13 to $88.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.17 to $89.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
- [F5]This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact|2026-07-02